Citigroup Inc Aptevo Therapeutics Inc. Transaction History

Citigroup Inc

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 10, 2022	SELL	$3.12 - $142.56 $93 - $4,276	-30 Reduced 75.0%	10 $0
Q2 2022 Aug 10, 2022	BUY	$3.26 - $6.3 $97 - $189	30 Added 300.0%	40 $0
Q3 2021 Nov 10, 2021	BUY	$15.01 - $22.16 $150 - $221	10 New	10 $0

Ticker APVO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 5,090,640
Market Cap $24.5M
Description
Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelo...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.